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Abstract
The management of osteoarthritis represents a real challenge. This complex and multi-factorial disease evolves over
decades and requires not only the alleviation of symptoms, i.e. pain and joint function but also the preservation of
articular structure without side effects. Nutraceuticals are good candidates for the management of OA due to their
safety profile and potential efficacy. However, they are not part of the treatment guidelines and published
recommendations. Curcumin is the yellow pigment isolated from the rhizomes of Curcuma longa, commonly
known as turmeric. Curcumin is a highly pleiotropic molecule with an excellent safety profile. Strong molecular
evidence has been published for its potency to target multiple inflammatory diseases. However, naturally occurring
curcumin cannot achieve its optimum therapeutic outcomes due to its low solubility and poor bioavailability.
Nevertheless, curcumin presents great potential for treating OA and has been categorized as having preclinical
evidence of efficacy. This review aimed at gathering most of the available information to document the potential
efficacy of curcumin based on the results obtained in in vitro models of cartilage and osteoarthritis and in other
diseases.
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Introduction
The management of osteoarthritis (OA) is a challenge. As
a multifactorial disease evolving over decades, OA is one
of the most disabling rheumatic diseases. In addition, no
cure has been discovered to date. There is growing inte-
rest in the medical management of OA. However, this area
requires new therapeutic strategies and approaches to deal
with OA in a rapidly growing elderly population.
The term “nutraceutical” is a combination of the words
nutrition and pharmaceutical. It defines foods or food-
derived products that provide health and medical benefits,
including prevention and treatment (Ameye and Chee
2006; Henrotin et al. 2011; Kalra 2003).
The benefit of such products comes not only from their
safety and efficacy but also by the fact that they are, by
definition, and by legislation, devoid of adverse effects.
Curcumin is the yellow pigment isolated from the
rhizomes of Curcuma longa, commonly known as tur-
meric (Henrotin et al. 2010; Shen and Ji 2012). Turmeric
powder contains 5% curcumin, which is the main biologi-
cally active phytochemical compound. Curcumin exists as
2 tautomeric forms, keto and enol. The enol form is the
most energetically stable in the solid phase or in solution.
In solution, keto-enol tautomers are present. Curcu-
min extracts are composed of curcumin demethoxy-
curcumin, bisdemethoxycurcumin, 50-methoxycurcumin
and dihydrocurcumin (Kurien et al. 2007). The latest being
both natural anti-oxidants (Masuda et al. 1999).
Curcumin is a highly pleiotropic molecule with an
excellent safety profile. Strong molecular evidence has
been published to support its potency for targeting mul-
tiple inflammatory diseases. However, naturally occur-
ring curcumin cannot achieve its optimum therapeutic
outcomes in vivo due to its low solubility and poor
gastrointestinal absorption and systemic bioavailability.
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Method
Based on our previous review (Henrotin et al. 2010),
curcumin represents great potential for the management
of OA. In addition, our narrative review (Henrotin et al.
2011) categorized curcumin as having preclinical evi-
dence of efficacy. The aim of the present review is to
summarize most of the latest information regarding the
therapeutic effects of curcumin in OA. A systematic
search for articles with keywords “curcumin” and “arth-
ritis” and “osteoarthritis” was performed in pubmed over
the past five years. Recent clinical trials were search on
www.clinicaltrials.gov. In addition, special attention was
given to the pharmacokinetic issues associated with
curcumin. Finally, data obtained with ArantalW (BioXtract,
Les Isnes, Belgium), high bioavailable turmeric extract in
OA patients in a recent observational cohort study
(OFKO survey) were discussed to illustrate the perspective
of curcumin in treating OA patients.
Clinical trials
A search on www.clinicaltrials.gov retrieved 75 clinical trials
with “curcumin” and 35 with “turmeric”. Eleven trials used
specifically turmeric extract. Taken together, it represented
a total of 86 different clinical trials. Among them, 27
focused on curcumin in cancer therapy, 18 on curcumin in
various inflammatory conditions including dermatitis, irri-
table bowel disease, colitis, 10 on curcumin in Alzheimer’s
disease and different neurological conditions, 4 in rheuma-
tology (including one in rheumatoid arthritis; two in OA;
and one in fibromyalgia) and 6 in diabetes or metabolic
syndrome. Ten of them aimed at studying various new
formulations or curcumin pharmacokinetics. Finally the last
eleven trials dealt with other conditions such as asthma,
cardiovascular diseases or effect in healthy volunteers.
Two clinical trials dealt with OA and curcumin. The
first one (ClinicalTrials.gov Identifier: NCT00792818)
compared the effect of Curcuma Domestica Extracts
(1500 mg/day divided into three times) to the one of
ibuprofen (1200 mg/day divided into three times) in
knee OA patients. This safety/efficacy study was based
on the evaluation of pain on a WOMAC subscale after
28 days of treatment. This study was completed but no
data have been available yet. The other trial dealing with
OA and curcumin was the one with ArantalW, a highly
bioavailable turmeric extract (ClinicalTrials.gov Identi-
fier: NCT00992004). Its efficacy was evaluated on pain
using a visual analog scale after 15 days of treatment.
This study was completed but the data not yet divulgated.
“Curcumin in Rheumatoid Arthritis” (ClinicalTrials.gov
Identifier: NCT00752154) is a clinical trial registered on
the Clinical Trials database. The study is sponsored by
University of California at Los Angeles. It is a randomized,
placebo-controlled crossover study in which 40 subjects
will receive a total of 4 g of curcumin per day (capsule
form, precise composition not disclosed) and then switch
to placebo. The subjects’ participation may last up to
8 months. By completion of the study, all 40 subjects will
have taken curcumin and placebo for 4 months each.
Subjects will have blood tests, complete questionnaires,
and be seen by the study doctor. At the present time sta-
tus of this study is unknown and it looks like the original
completion deadline will not be met and a larger and
more comprehensive clinical trial may be necessary. How-
ever, when the study is completed it will be interesting to
see if curcumin has provided any benefits for RA patients
as this information will be useful for the design of future
clinical trials of curcumin in OA.
These clinical trials illustrate the ongoing interest in
curcumin and its applicability to a wide range of diseases.
Systematic review
Therapeutic potential of curcumin
Curcumin has been used for centuries in traditional
Chinese and Ayurvedic medicine for its anti-inflammatory
properties (Goel et al. 2008). Turmeric has at least 53 dif-
ferent names in Sanskrit, each one referring to specific
properties, including jawarantika, which destroys fever,
mehagni, killer of fat, or rabhangavasa, which dissolve fat
(Aggarwal 2010). Over the last few decades many scientific
and clinical studies have focused on the potential of
curcumin for treating various pathological conditions.
Curcumin was investigated mainly for its anti-
inflammatory and anti-oxidant potency. Oxidative damage
and inflammation are now known to be a root cause of
cancer and neurodegenerative diseases (Basnet and
Skalko-Basnet 2011). Recently, these therapeutic effects
have been reviewed in depth by Gupta et al. (Gupta et al.
2012b; Gupta et al. 2012a). Herein, a particular attention
was paid to the potential therapeutic effects of curcumin
on OA.
Curcumin in obesity, insulin resistance and diabetes
Obesity is a major risk factor for type 2 diabetes, athero-
sclerosis, cancer and other chronic diseases. Metabolic
syndrome is defined as obesity, type 2 diabetes, hyper-
tension and dyslipidemia (Aggarwal 2010). All these
pathologies are closely linked to insulin resistance. This
condition is closely related to OA. Indeed, OA has been
shown to be induced, at least in part, by metabolic syn-
drome (Velasquez and Katz 2010). In addition, inflam-
mation has been strictly linked to all these conditions
(see (Aggarwal 2010) for review). Curcumin has been ex-
tensively studied as a treatment of obesity and obesity-
related metabolic diseases (Aggarwal 2010). Curcumin
was shown to directly interact with adipocytes, pancreatic
cells, hepatic stellate cells, macrophages and muscle cells.
Curcumin has been shown to reverse insulin-resistance,
hyperlipidemia, hyperglycemia and other symptoms linked
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to obesity through the interaction with various key
mediators, most of them are also involved in OA patho-
physiology. Indeed, curcumin (5 μM) was shown to down-
regulateTNF-.alpha; production in various tissues (Chan
1995). In addition, curcumin suppressed NF-κB
through the inhibition of IκBα degradation at
concentrations ranging from 2 to 60 μM (Singh and
Aggarwal 1995) and reduced the NF-κB-regulated
adipokines, including chemokines (MCP-1, MCP-4,
eotaxin) at concentrations ranging from 0.1 to 10 μM
(Woo et al. 2007) and interleukins (IL-1β, IL-6 and
IL-8) at concentrations ranging from 5 to 20 μM
(Wang et al. 2009). It also suppressed cyclooxygenase
(COX)-2 and vascular endothelial growth factor
(VEGF) through the inhibition of IKK activation
(Aggarwal et al. 2006). Curcumin (20-40μM) was
shown to be able to suppress plasminogen activator
inhibitor type-I through the inhibition of the tran-
scription factor early growth response (Egr)-1 gene
product (Pendurthi and Rao 2000) and to down-
regulate the secretion of insulin growth factor (IGF)-1
and to inhibit IGF-1 binding protein-3 (Xia et al.
2007). Furthermore, curcumin (10–50 μM) mimicked
most of anti-diabetic drugs by activating PPARγ in
hepatic stellate cells (Xu et al. 2003). It acted on cell
signaling pathways by downregulating c-jun NH2 ter-
minal kinase (JNK) at concentrations ranging from
5 to 20 μM (Wang et al. 2009). Curcumin (20 μM)
also acts on developmental pathways by inhibiting the
Wnt/β-catenin pathway in adipocytes (Jaiswal et al.
2002). This effect was demonstrated to occur with
concentrations of 20 and 40 μM through the down-
regulation of the transcription co-activator p300 (Ryu
et al. 2008) or through the inhibition of the glycogen
synthase kinase (GSK) 3β responsible of β-catenin
phosphorylation at concentrations of 1 and 10 μM
(Bustanji et al. 2009). Finally, curcumin (5–30 μM)
was shown to interrupt leptin signaling by reducing
the phosphorylation levels of leptin receptor (Ob-R)
and downstream targets (Tang et al. 2009) and it
increased the expression of adiponectin, which nega-
tively regulates obesity when supplied as dietary
curcumin in obese mice (Weisberg et al. 2008). Thus
curcumin acts directly and strongly in mechanisms
that sustain obesity and inflammation. In addition,
most of these signaling intermediates and mediators
also play key role in OA pathophysiology.
Potential therapeutic effects of curcumin in osteoarthritis
Many evidences support the use of curcumin in OA (Shen
et al. 2012). Most of the biological effects observed and
published for curcumin in chondrocytes and OA between
2002 and 2009 were reported in our previous narrative
review (Henrotin et al. 2010). The following section will
present the most recent data reported for curcumin and
OA.
In vitro and in vivo mechanisms of action
Anti-inflammatory activity
The anti-inflammatory property of curcumin has been
known for centuries. It has been investigated and
explained by studies showing how curcumin acts on in-
flammatory pathways. Curcumin (50 μM) was shown to
inhibit NF-κB activation and translocation induced by
IL-1β and the consequent expression of NF-κB induced
pro-inflammatory genes, COX-2 and VEGF (Csaki et al.
2009). The effects of curcumin have been documented
through its impact on cell signaling. Another study has
described its effect on signaling and its inhibitory po-
tency in chondrocytes in agarose constructs (Chowdhury
et al. 2008). In this culture model, curcumin (0.01-100
ng/ml) was used for its potency to inhibit activator pro-
tein (AP)-1 and was then shown to reverse the IL-1β
stimulated production of nitric oxide (NO) and prosta-
glandin E2 (PGE2).
The effect of curcumin (1–20 μM) has been also tes-
ted in vitro on human articular chondrocytes in alginate
beads (Mathy-Hartert et al. 2009). This in vitro study
demonstrated no toxic effect of curcumin on cell viability.
Furthermore, it was able to produce an anti-inflammatory
effect by inhibiting the pro-inflammatory mediators, i.e.
PGE2, NO, IL-6 and IL-8. In bovine chondrocytes in
monolayer, the biological activity of indomethacin,
celecoxib and curcumin have been compared. Interes-
tingly, curcumin but not non-steroidal anti-inflammatory
drugs inhibited NO production. As anticipated, curcumin
was less effective on PGE2 (IC50 = 2.5μM) production
than NSAIDs (IC50 < 2.5 μM). However, in contrast to
NSAIDs, curcumin inhibited COX-2, but not COX-1 gene
expression (Mathy et al. 2007).
The anti-inflammatory potency of curcumin was also
demonstrated in another connective tissue cell type.
Curcumin (5μM) was shown to modulate inflammation
in human tenocytes (Buhrmann et al. 2011) by the inhib-
ition of COX-2 through its effect on NF-κB and on other
related and equally important cell signaling pathway -
the phosphatidylinositol-3 kinase/Akt pathway. The
shared lineage and phenotypic similarities between car-
tilage and tendon cells suggest that curcumin would
have similar effects on these connective tissues.
Anti-catabolic/anabolic effects
The anti-inflammatory potency of curcumin has been
revealed by its ability to inhibit NF-κB activation, thus
producing anti-catabolic effects. The inhibition of NF-κB
by curcumin (50 μM) had significant effect on NF-κB
-induced matrix degradation gene products (Csaki et al.
2009). This effect was shown in a study of a combination
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treatment with curcumin and resveratrol. Resveratrol or
trans-3,5,40-trihydroxystibene is a polyphenolic, antifungal
natural phytoalexin found in grapevines (Vitis vinifera)
and a variety of other plants and has been shown to pos-
sess potent anti-inflammatory and anti-oxidant properties.
Curcumin alone or in combination with resveratrol
reversed type II collagen inhibition induced by IL-1β. The
combination treatment with resveratrol produced a syner-
gistic effect. Another study revealed that curcumin (50
μM) produced anti-catabolic effect by the inhibition of
MMP-9 through the inhibition of NF-κB activation
(Shakibaei et al. 2007). The previously mentioned work
with highly bioavailable curcumin (Mathy-Hartert
et al. 2009) confirmed the anti-catabolic potency of
curcumin in human chondrocytes by the inhibition of
MMP-3, but failed to modify aggrecan production. In
addition, curcumin (0.1-100 μM) tested on equine
cartilage explants stimulated with IL-1β (10–25 ng/
ml) showed the suppression of glycosaminoglycan
(GAG) release (Clutterbuck et al. 2009). Anti-
catabolic effects were also demonstrated in tenocytes
(Buhrmann et al. 2011) by the inhibition of several
matrix metalloproteinase (MMP) synthesis (MMP-1,
MMP-9 and MMP-13) induced by IL-1β. Thus
curcumin might be able to reverse the imbalance be-
tween anabolic and catabolic factors that occur in OA
joint tissues by reducing the catabolic part. By this
way, curcumin could prevent cartilage degradation
and promote the accumulation in the extracellular
matrix of newly synthesized matrix components like
aggrecan.
The effects of curcumin have also been studied in
adult mesenchymal stem cells. Curcumin (5 μM) was
demonstrated to promote chondrogenesis of mesen-
chymal stem cells maintained in a high-density co-
culture microenvironment by antagonizing the effects
of pro-inflammatory cytokines (Buhrmann et al.
2010). All together these results support the potential
structural and functional effects that curcumin could
exert on joint tissues in OA.
Effect on cell survival and anti-apoptotic potency
Another important feature of curcumin in OA is its
effect on cell survival. Indeed, it was not only proven
to be safe for chondrocytes (Mathy-Hartert et al.
2009) but also shown to counteract the cytotoxic
effect induced by IL-1β (Csaki et al. 2009). It was
able to influence the changes that occur in mitochon-
drial such as swelling due to IL-1β stimulation and
apoptosis. Curcumin reduced the apoptotic features
induced by IL-1β. In addition, it stimulated anti-
apoptotic factors (Bcl-2, Bcl-xL and TRAF1) and
inhibited pro-apoptotic factors (caspase-3) (Csaki
et al. 2009).
Clinical efficacy
Only a few clinical studies have been published with
curcumin. One study tested the clinical efficacy of a
herbomineral formulation containing a component rich
in curcumin in subjects with OA (42 patients) in a one-
month randomized, double-blind, placebo-controlled,
cross-over study (Kulkarni et al. 1991). Treated group
reported a positive effect on pain and mobility. More
recently, the clinical efficacy of curcumin was tested in
OA patients receiving MerivaW, a patented complex
with phosphatidylcholine that improved curcumin
bioavailability (Belcaro et al. 2010). Based on a previous
study over 50 OA patients showing that MerivaW
improved joint pain and function, this study inves-
tigated efficacy and safety of the compound on a longer
term (8 months). The evaluation included the measure-
ment of several markers of inflammation (IL-1β, IL-6,
sCD40L, sVCAM-1, ESR). One hundred OA patients
were included in this study. They fulfilled the criteria
for primary knee OA (grade 1 or 2). Patients were
divided into 2 groups, one receiving “the best available
treatment” as defined by patient’s general practitioner
and specialists and the other receiving “the best
available treatment and MerivaW”. In this last group,
patients received two 500 mg Meriva tablets daily, one
after breakfast and one after dinner (1000 mg/day
corresponded to 200 mg curcuminoids/day). The com-
position of the MerivaW tablets was a natural cur-
cuminoid mixture (20%), phosphatidylcholine (40%),
and microcrystalline cellulose (40%). The composition
of the curcuminoids mixture was 75% curcumin, 15%
demethoxycurcumin and 10% bisdemethoxycurcumin.
MerivaW significantly reduced pain and stiffness and
improved joint function. All WOMAC scores were
improved by the treatment with MerivaW, including
social and emotional function. The improvement of
physical function was also noteworthy. Finally, the
markers of inflammation were significantly decreased in
the treatment group between enrollment and after 8
months of treatment.
Curcumin was tested in patients suffering rheumatoid
arthritis (Chandran and Goel 2012). In addition to be
safe and not related to any adverse events, curcumin
(500 mg) was the most effective to improve disease ac-
tivity score (DAS) and American College of Rheumatol-
ogy (ACR) score. Curcumin was administered alone or
in combination with diclofenac sodium (50 mg).
Despite the paucity of published clinical data on
curcumin and the overall poor quality of the trials, there
is scope for promising future studies on curcumin in
OA. However, since the in vitro effect was so well-
documented and proven, the clinical efficacy needs to be
further studied in OA patients. To this aim, one may
keep in mind the importance of well-designed trials.
Henrotin et al. SpringerPlus 2013, 2:56 Page 4 of 9
http://www.springerplus.com/content/2/1/56
Nevertheless, it also remain to undercover the precise
mechanism of action of curcumin and to explain how it
could achieve the effects that have been observed
in vitro with supra-physiological concentrations, in
human where its bioavailability could represent a chal-
lenge. Finally, this is important to note that curcumin
when used in vitro, was dissolved in ethanol, acetone or
dimethyl sulfoxide (DMSO).
Pharmacokinetic issues
Absorption and distribution
Globally the pharmacokinetic profile of curcumin is
characterized by a low serum concentration and a
limited tissue distribution (Aggarwal and Sung 2009;
Goel et al. 2008; Anand et al. 2007; Sharma et al. 2005;
Dhillon et al. 2008). The available clinical data supports
this notion. The serum concentration of curcumin peaks
1-2h after an oral dose in human subjects with peak
serum concentrations of 0.5, 0.6 and 1.8 μM at massive
doses of 4, 6 and 8 g/day (Cheng et al. 2001). Curcumin
glucuronide and sulfate conjugates can be detected in
plasma after oral administration (Vareed et al. 2008).
Plasma curcumin, curcumin sulfate and curcumin
glucuronide concentrations were in the range of 10 nM
1h after a large 3.6 g dose of oral curcumin (Sharma
et al. 2004). Curcumin and its glucuronidated and
sulfated metabolites can be measured in urine after a
dose of 3.6 g/day (Heath et al. 2003) but cannot be
detected in plasma at a dose lower than 3.6 g/day. Pure
curcumin (2000 mg) administered to fasting healthy
volunteers showed low curcumin concentration in
plasma (<10 ng/ml) observed 1h after consumption
(Shoba et al. 1998). High doses (8000 mg) of curcumin
administered daily for 3 months to patients with pre-
invasive malignant or high-risk pre-malignant conditions
showed peak serum concentrations (1.75 μM) achieved
after 1-2h oral intake and gradual decline of the levels
within 12h (Cheng et al. 2001).
A pilot study with 15 patients with advanced colorec-
tal cancer used standardized oral curcumin extract (each
capsule contained 20 mg of curcuminoids (18 mg of
curcumin and 2 mg of desmethoxycurcumin) suspended
in 200 mg of essential oils derived from Curcuma spp.)
daily up to 4 months. This study showed no toxicity but
no evidence of detectable systemic bioavailability was
provided either (Sharma et al. 2001). A curcuminoid for-
mulation (each capsule contained 500 mg: 450 mg of
curcumin, 40 mg of desmethoxycurcumin and 10 mg of
bisdesmethoxycurcumin) administered orally for up to 4
months and allowing a rapid dose escalation that
equated to curcumin doses between 450 and 3,600 mg
daily showed that the later daily dose (3,600 mg) resulted
in detectable levels of the compound and its conjugates
in plasma. It was also present in urine (0.1-1.3 μM
curcumin; 19–45 nM curcumin sulfate; 210–510 nM
curcumin glucuronide). However, it was not detectable
in patients who received doses less than 3,600 mg daily
(Sharma et al. 2004). Finally high doses (12 g/day) of
curcumin in phase I preclinical trial reinforces the low
systemic bioavailability (Lao et al. 2006).
Interestingly, curcumin has been shown to accumulate
in gastrointestinal tissues. Detectable levels of curcumin
were found in both malignant (patients undergoing colo-
rectal cancer surgery) and normal colorectal tissues after
7 days of curcumin 450, 1,800 or 3,600 mg/day orally
(Garcea et al. 2005). The concentration of curcumin in
normal tissue was 12.7 nmol/g of tissue, and in malig-
nant colorectal tissue, 7.7 nmol/g of tissue. Curcumin
sulfate and glucuronide were identified in these tissues.
Low nanomolar levels of curcumin and its metabolites
were measured in peripheral blood samples taken 1h
after seventh dose of curcumin and in portal blood
samples taken 6-7h after seventh dose of curcumin.
However, parent drug was not detected in liver tissue of
liver metastases of colorectal cancer but trace of the
metabolic products (Garcea et al. 2004). A recent pilot
study has demonstrated that after 14-days treatment
with 2.35 g of curcumin-C3-complex, curcuminoids
were detectable in all 23 participants biopsies (mean
value 48.4 μg/g) but failed to induce deleterious effects
on colonic mucosa (Irving et al. 2012).
New treatments with naturally occurring curcumin in
its original form represent a major concern due to its
low bioavailability. After oral ingestion, very little may
actually reach the systemic circulation and even less may
reach joint tissues. The dose of oral curcumin required
to produce hepatic levels sufficient to produce pharma-
cologic activity is not feasible in humans with this
pharmaceutical formulation (Basnet and Skalko-Basnet
2011). An important question addressed by a recent re-
view (Shen and Ji, 2012) is “how can curcumin be potent
in the face of low bioavailability”. There is a need for
improvement of the formulation of curcumin and/or
delivery system and many attempts have been made
(Padhye et al. 2010). To bypass the intestinal metabolic
enzymes, curcumin can be dissolved in oil before inges-
tion. Dissolution in oil produces no modification of
its structure. It can then be directly absorbed into
chylomicrons and subsequently into the lymphatic system
then bypassing the liver and “the first pass phenomenon”
(Anand et al. 2007). In this context it is important to note
that the turmeric used in Indian culinary traditions is ini-
tially heated and dissolved in oil. Another attempt was
made by the co-administration of curcumin and piperine
(Shoba et al. 1998). Indeed, piperine, as an inhibitor of
hepatic and intestinal glucuronidation enhanced the serum
concentration and bioavailability of curcumin in both
humans and animals.
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Other solutions to improve bioavailability could come
from liposomal delivery system (Basnet et al. 2012),
nanoparticles (Anand et al. 2010) or other drug delivery
systems (Bansal et al. 2011). The other possibility could
tend to counteract curcumin metabolism by the intra-
articular injection of high doses of curcumin to reach
concentrations producing in vitro effects (Henrotin et al.
2010). Thus far there are no studies that have attempted
intra-articular injection of high doses of curcumin. Sui-
table large animal models are required for such studies.
Finally, the improvement of the bioavailability of
curcumin is a challenge. It could be improved by diffe-
rent techniques, such as heat-treatment (Kurien et al.
2007) or solubilized in dilute alkali (Kurien and Scofield
2007).
Highly bioavailable formulation of curcumin has been
developped. ArantalW is an innovative and patented for-
mulation of curcumin, designed to increase the bioavail-
ability of the active component curcumin in human
(Figure 1). Bioavailability improvement was based on the
increase of curcumin solubility in duodenal conditions;
higher solubility was achieved by the pre-formulation of
potential micro-emulsions, obtained in the digestive
system (stomach, intestine) after disintegration of the
capsule. The ideal conditions for the formation of
micro-emulsions were made possible thanks to the pre-
sence of a high HLB (Hydrophilic-Lipophilic Balance)
emulsifier: Polysorbate 80 (Tween 80W) combined to
curcumin in a well-defined ratio. To improve the stabi-
lity of the active part in the capsule, the presence of a
weak acid was essential. The adjunction of little amount
of turmeric essential oil during the micro-emulsion
process still increased the solubility of curcumin. In this
formulation, the solubility of curcumin in duodenal
conditions (pH 6.8, 37C) has been multiplied by a fac-
tor of 7.500, compared to the same amount of “native”
curcumin.
A Phase I pharmacokinetics study on ArantalW, a high
bioavailable turmeric extract with a water solubility
increased 4000 times was run on 2 groups of 12 healthy
individuals. The AUC obtained with ArantalW is
compared to the one of other formulations of curcumin
(Table 1). Each group received orally 1 (42 mg
curcumin) or 2 capsules (84 mg of curcumin) of
ArantalW respectively. With 2 capsules administered
orally, the mean of Cmax on 12 individuals was 0.9 μM,
with a statistical extrapolation at 1.6 μM with 4 capsules
(administering 84 mg and 168 mg of curcumin respec-
tively). These values were obtained after hydrolysis of
conjugated metabolites by means β-glucuronidase and
arylsulfatase (personal communication according to the
analysis of the report performed by Advanced Techno-
logy Corporation M1060 Advanced provided by
BioXtract S.A.; unpublished data).
Metabolism
The metabolism of curcumin after oral administration is
rapid and the consequent bioavailability in systemic circu-
lation is low (Ireson et al. 2002). Curcumin is conjugated
to produce curcumin glucuronides and sulfates or it is
reduced to hexahydrocurcumin in the liver or in the intes-
tine. The intra-peritoneal or systemic administration leads
to the reduction of curcumin into tetrahydrocurcumin,
hexahydrocurcumin and octahydrocurcumin (Ireson et al.
2002; Garcea et al. 2005). Curcumin has lower stability
and can degrade under physiological conditions. The
degradation products have been identified as trans-6-
(40-hydroxy-30-methoxyphenyl)-2,4-dioxo-5-hexenal, ferulic
acid, feruloyl methane and vanillin. The metabolic
derivatives of curcumin do not possess the same bio-
logical activities as the original compound and were
shown to be biologically inactive (Sandur et al. 2007;
Ireson et al. 2001; Pan et al. 2000). However, some of its
degradative products as ferulic acid or vanillin can be
associated with anti-oxidant activity (Hatcher et al.
2008). In addition, the low stability of curcumin in
aqueous solution is due to its hydrophobic nature
(Aggarwal and Sung 2009). On the contrary, its de-
gradative products have greater aqueous solubility than
curcumin itself.
Elimination
Pharmacokinetic information was also obtained from
animal models. Curcumin (1000 mg/kg) adminis-
tered orally to rats showed excretion of 75% of the
administered dose in the faeces and negligible amount
detected in urine (Wahlstrom and Blennow 1978). The
majority of curcumin ingested by rats is excreted
in faeces (35% unchanged and 65% as metabolites)
(Ravindranath and Chandrasekhara 1981). Curcumin is
absorbed via the intestine with possible enterohepatic
recirculation.
POLYSORBATE
CURCUMINE
MICELLE
Figure 1 ArantalW, a highly bioavailable curcumin.
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ArantalW : a high bioavailable turmeric extract
ArantalW (Brand name, FlexofytolW, Tilman S.A., Somme-
Leuze, Belgium), the high bioavailable turmeric extract
described above, was evaluated in an observational
cohort study, the OFKO survey (personal communication
according to the report DIM 3 provided by BioXtract S.A.
unpublished data). This study was fully sponsored and
conducted by the manufacturer of ArantalW (Tilman S.A.).
1463 patients were recruited. Among them, 1077 patients
suffering from OA (64.6 ± 12.4; mean ± SD) were included
in the study. 99.2% of the patients were taking NSAID and
among them 36% were polymedicated. Otherwise, poly-
medication consisted in glucosamine sulfate (10.5%) with
or without chondroitin sulfate (alone 0.8% or in combin-
ation 22.2%), type II collagen (2.5%), intra-articular hyalur-
onic acid (4.3%) or corticosteroids (1.6%). Interestingly
only 1% of patients were using acetaminophen. Patients
were asked to take 4 capsules of FlexofytolW (2x2
capsules/day or 2 x 84 mg of curcumin) maintaining their
medication for 3 months. Pain was evaluated using VAS
on 3 visits throughout the study. FlexofytolW was well
tolerated. The reported side effects were very rare and
minor (19 patients reported adverse effects - essentially
nausea and bloating). 93.45% of the patients decided to
remain on FlexofytolW after the first visit, among them
70.56% maintain also the 4 capsules a day. Results
revealed a significant pain reduction of 48% over the 3
visits in the group of 1077 OA patients, with a mean re-
duction of 32.45mm. This effect improved over time. Of
special note, MCII (minimum clinical important improve-
ment corresponding to a decrease of 19mm on the VAS
scale) was obtained for 81% of patients. In addition, a
majority of patients using FlexofytolW reported that they
didn’t need any more any other concomitant medications
(only 9% of patients kept NSAIDs, 16% other drugs and
85% acetaminophen). 93.45% of patients decided to main-
tain FlexofytolW in their medication for OA after the study
ended due to their overall satisfaction with the product.
Conclusion
Nutraceuticals are not part of the published OARSI and
EULAR recommendations for the management of OA
(Zhang et al. 2008, 2007; Zhang et al. 2010; Jordan et al.
2003; Zhang et al. 2005). The promising in vitro results
and the interesting clinical observations gathered here
for curcumin should refocus efforts to develop therapies
based on new formulations of curcumin. Well-designed
clinical studies are needed to determine and document
the efficacy of curcumin and combination products with
curcumin in OA patients. Due to the increased bioavail-
ability obtained with certain formulations, we expect
improved bioavailability and consequently enhanced
clinical efficacy. New formulations of curcumin should
demonstrate improved pharmacokinetic and clinical effi-
cacy. Curcumin is still worthy of our interest and re-
search efforts and needs to be further studied in clinical
trials.
Hence, curcumin represents a new paradigm since it is
not yet a recommended intervention in OA but should
be considered based on its safety and efficacy. In
addition, taken altogether, these data highlight the needs
in OA research for the near future as good quality and
well-designed trials.
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